HomeMedical NewsCharacterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials
General Medicinegeneral
Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials
PLOS MedicineMay 29, 20263 min readReliability 96%
Written & Analyzed by
Abgrat Medical Intelligence Team
Medically Reviewed by
Abgrat Medical Review Board
Board-certified physicians and AI researchers
Source Reliability: 96%Last Reviewed: Jun 2026
Cross-referenced with trusted medical databases:
WHO GuidelinesNIH PubMedCDC Clinical ResourcesNEJM Evidence
⚕️ This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Related Medical Articles
References & Sources
①PLOS Medicine — Primary source for this article
②AI analysis conducted by Abgrat Medical Intelligence Engine using validated clinical databases
③Cross-referenced with WHO, NIH, CDC, and NEJM clinical guidelines
Original Source
PLOS Medicine — https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004609Published: 2026-05-29T14:00:00.000Z |Analyzed by Abgrat AI: 2026-06-26